QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in children
QIAGEN announced the endorsement of its QuantiFERON-TB Gold Plus test by the American Academy of Pediatrics (AAP) for detecting latent tuberculosis (TB) in children of all ages. The AAP's new guidelines recommend using modern blood-based tests, such as IGRA, to screen at-risk children, emphasizing their accuracy and efficiency over traditional skin tests. This adjustment aligns with broader U.S. trends shifting towards improved TB control methods, especially important given the recent 16% increase in active TB cases in the U.S. The updated guidelines are expected to enhance early detection and treatment, preventing the progression to active TB disease.
- AAP's endorsement of QuantiFERON-TB Gold Plus for all ages can boost QIAGEN's market share.
- The new guidelines reflect a shift towards more accurate, modern TB tests, benefiting QIAGEN.
- Increased TB detection in children may lead to higher sales of QIAGEN's blood-based tests.
- The rising TB cases in the U.S. indicate a substantial public health concern, necessitating effective control measures.
The updated guidelines from the American Academy of Pediatrics (AAP) to recommend the use of interferon-gamma release assays (IGRAs) such as QuantiFERON-TB Gold Plus for TB screening in children signal a significant shift towards modern diagnostic methods. This move aligns with global trends and underscores the importance of precise detection for preventing progression from latent to active TB.
IGRAs offer a more reliable alternative to the traditional tuberculin skin test (TST), particularly in individuals with prior Bacillus Calmette-Guérin (BCG) vaccination. The ability to avoid the limitations of TST by using IGRAs can lead to more accurate diagnosis, fewer follow-up visits and faster treatment initiation. This is important for children, who are at higher risk for TB progression and often exposed in environments like schools and childcare centers. The adoption of these guidelines could accelerate the eradication of TB by improving early detection and treatment outcomes.
For retail investors, the expansion of IGRA guidelines provides a strong validation of QIAGEN's QuantiFERON-TB Gold Plus, potentially driving higher demand and broader market adoption. This could have a positive impact on QIAGEN's revenue and market share in the diagnostics sector.
From a market perspective, the AAP's endorsement of QuantiFERON-TB Gold Plus for TB screening in children could significantly benefit QIAGEN. The increased adoption of IGRAs over the outdated TST presents an opportunity for QIAGEN to capture a larger segment of the TB screening market. With approximately 13 million Americans potentially harboring latent TB and an annual increase in active TB cases, the demand for reliable and efficient diagnostic methods is likely to grow.
Moreover, the guidelines align with the broader trend of healthcare providers and public health organizations favoring blood-based tests for their accuracy and efficiency. Retail investors should note the potential for increased sales volume and the strategic advantage this provides QIAGEN in the diagnostics market.
American Academy of Pediatrics in the United States now recommends IGRA tests like QuantiFERON-TB Gold Plus to screen at-risk children of all ages // New recommendation joins trend of U.S. tuberculosis control guidelines that emphasize use of modern blood-based tests to combat the spread of potentially deadly bacterial infection
Germantown, Maryland, and Venlo, the Netherlands, June 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomes new guidelines in the United States that recommend screening at-risk children of all ages for latent tuberculosis (TB) infection with modern blood-based tests such as QIAGEN’s market-leading QuantiFERON-TB Gold Plus (QFT-Plus).
The new guidelines from the American Academy of Pediatrics (AAP) emphasize testing for TB with modern interferon-gamma release assays (IGRAs). The new standards were published in the academy’s Red Book: 2024–2027 Report of the Committee on Infectious Diseases.
The new TB screening guidelines expand on the organization’s previous IGRA recommendations and now cover children of all ages, including infants and children age 2 and under.
Up to 13 million people in the U.S. are estimated to have latent TB infections, and children are at increased risk for progression from infection to contagious active TB disease. Children are also commonly exposed to settings with a higher risk for TB transmission, such as schools and childcare centers.
The AAP’s recommendations follow recently updated guidelines from the American College Health Association (ACHA) stating that IGRAs are preferred over the 120-year-old tuberculin skin test (TST) for most situations relevant to college health.
“I am pleased to see the American Academy of Pediatrics removing any age threshold for the use of IGRAs,” said Dr. Lindsay Cameron, an AAP member, pediatric infectious disease physician and pediatrician in Houston, Texas. “The new guidelines resonate with the growing recognition by TB control experts of the value of using the most accurate diagnostic tests available. As part of our comprehensive efforts to eradicate this life-threatening disease, latent TB infection can be detected in at-risk children and adolescents and treated to prevent progression into active and contagious TB disease.”
“Identifying TB infection in children is critical to prevent the spread of TB in the United States,” said Jenny Howard, Vice President, Head of the Immune Response Franchise at QIAGEN. “The expanded AAP recommendations will lead to better detection of TB infection in young children so that they can benefit from preventive treatment. Our customers can now rely on QFT-Plus as the modern gold standard for blood-based tuberculosis detection for patients of all ages.”
The updated childhood TB screening guidelines come as U.S. authorities are expanding the role of latent TB screening in national tuberculosis control efforts.
QIAGEN recently announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on new US CDC tuberculosis screening guidelines that require the use of IGRA tests to ensure a safe immigration process and support the global fight against TB.
Tuberculosis is a contagious bacterial infection spread primarily through coughing by patients with the active pulmonary form of the disease. One in four people worldwide are believed to have latent TB infections, with 5
QuantiFERON-TB Gold Plus is the world’s leading IGRA blood test, with millions of tests performed annually. It is established as a superior alternative to the dated TB skin test (TST), which is less effective in identifying TB infection in people who have received BCG vaccination, which is common for patients from high-TB-burden countries, and in patients who may be unlikely to return for TST interpretation. QuantiFERON-TB Gold Plus has helped patients and providers globally by reducing the number of visits to a single blood draw with a faster turnaround time. 70–80 million TB skin tests are performed each year globally, including 16–18 million in the U.S., with healthcare providers increasingly switching to modern IGRA tests.
To learn more about QuantiFERON-TB and tuberculosis control, please visit www.qiagen.com/EndTB.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2024, QIAGEN employed more than 5,900 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Corporate
![](https://ml.globenewswire.com/media/ODA4NDYzOTgtNjNkOS00Nzg4LWFkNTktOTY2OGY5NjAzM2UyLTEwMzA5NDM=/tiny/QIAGEN-N-V-.png)
FAQ
What are the new U.S. guidelines for detecting tuberculosis in children?
Why was QuantiFERON-TB Gold Plus recommended by the AAP?
How do the new guidelines affect QIAGEN (QGEN)?
What impact do the updated guidelines have on tuberculosis control in the U.S.?